Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer
Photochemical & Photobiological Sciences · 2026
DOI: 10.1007/s43630-026-00977-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Photochemical & Photobiological Sciences, 2026. Verfasst von Hey Young Yoon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Iridium, Photochemotherapy, Erlotinib Hydrochloride, Photosensitizing Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
Photodynamic therapy (PDT) offers superior spatiotemporal control compared with conventional cytotoxic cancer therapies through localized light activation. However, most photosensitizers rely on passive tumor accumulation and lack intrinsic mechanisms for active cancer cell targeting. Here, we report Ir_Erl , the first cyclometalated iridium (III) photosensitizer covalently conjugated to the EGFR inhibitor erlotinib through C10 alkyl linker. Ir_Erl retains the bright phosphorescence of the [Ir(pq) 2 (bpy)] core, enabling label-free imaging and intracellular tracking, while efficiently generating singlet oxygen through a strictly light-dependent type II reactive oxygen species (ROS) generation pathway. Ir_Erl preferentially accumulates in cancer cells relative to non-cancerous controls, and its uptake is markedly reduced by EGFR pre-blockage with gefitinib, indicating an EGFR-dependent accumulation mechanism. Upon white-light irradiation, Ir_Erl exerted potent photocytotoxicity (IC 50 ~ 13 µM) while maintaining minimal dark toxicity (> 100 µM). In contrast, erlotinib alone displays no detectable phototoxicity under identical conditions. Collectively, these results demonstrate that Ir_Erl integrates receptor-directed delivery with efficient light-triggered ROS generation, establishing a modular strategy for the development of tumor-selective, light-activatable metal-complex photosensitizer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Korea University College of Medicine, Seoul, Korea.
- School of Transdisciplinary Innovations & Department of Chemistry, Seoul National University, Seoul, Korea. junseoklee@snu.ac.kr.
- National Research Laboratory for Convergence Degradation Biology (NRLDB), Korea University, Seoul, Korea. junseoklee@snu.ac.kr.
Förderung
- Seoul National University
Zitieren
APA
Yoon, H. Y., Lee, J. H., & Lee, J. S. (2026). Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer. Photochemical & Photobiological Sciences. https://doi.org/10.1007/s43630-026-00977-y
Vancouver
Yoon HY, Lee JH, Lee JS. Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer. Photochemical & Photobiological Sciences. 2026. doi:10.1007/s43630-026-00977-y
BibTeX
@article{Yoon2026,
author = {Yoon, Hey Young and Lee, Jung Hoon and Lee, Jun-Seok},
title = {Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer},
journal = {Photochemical & Photobiological Sciences},
year = {2026},
doi = {10.1007/s43630-026-00977-y}
}
EUVIMED